Michel Gagner

EndoGastric Solutions, Inc. develops natural orifice surgical products and procedures to advance the treatment of gastrointestinal diseases. The firm offers EsophyX device and StomaphyX device. The company was founded by Stefan J. M. Kraemer, Clifton A. Alferness, Scott Jordan Wolf, James W. Fitzsimmons and John M. Adams in 2003 and is headquartered in Redmond City, WA.

Cephea Valve Technologies, Inc. provides medical devices. Its technology is being developed to provide an option for people whose diseased mitral valves need to be replaced. The artificial valve is designed to be delivered through a vein in the leg, forgoing the need for open-heart surgery. Replacement of the diseased mitral valve restores normal blood flow through the heart. The company was founded by Thierry Bernard Thaure and is headquartered in Santa Clara, CA.

FlexDex, Inc. engages in the provision of robotic surgery. It engages in research of parallel kinematics, virtual center of rotation, and flexure mechanisms at the school’s precision systems design lab. The firm enhances the capabilities of all MIS instruments and endoscopes. The company was founded by James D. Geiger, Shorya Awtar and Gregory Bowles and is headquartered in Brighton, MI.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

TriFlo Cardiovascular, Inc. operates as a biotechnology company. The company was founded in 2017 and is headquartered in Huntington Beach, CA.

Aquyre Biosciences, Inc. is a biotech company that created Celtivity™, a rapid digital specimen adequacy assessment tool that can identify the presence of cancer cells and immune cells in a biopsy in just two minutes. The company is based in Weston, MA and was founded by Bertrand Le Conte de Poly, Claude Boccara. The assessment is presented as a cellular heatmap, making analysis and detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. Floyd Samuel Eberts has been the CEO of the company since 2023.